Abstract: The invention relates to a method of modifying a yeast cell for the production of ethanol. According to some embodiments of the invention, the activity of the Gpd1 protein and/or the Gpd2 protein is reduced.

Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO. The invention additionally provides methods of using such microbial organisms to produce BDO.

Abstract: The present invention relates to methods for producing variants of a parent TY145 subtilase and of a parent BPN? subtilase and to TY145 and BPN? variants having altered properties as compared to the parent TY145/BPN? subtilase.

Abstract: Methods of qualitatively and/or quantitatively detecting the presence of mutations, modifications or impurities in a protein sample are provided. The methods utilize isotopically labeled variants of amino acids incorporated into proteins prior to protein digest to enable comparisons of two protein samples in bottom-up liquid chromatography.

Abstract: The invention relates to a novel 3D structure encoding a Nocardiopsis protease, as well as to variants of parent protease homologous to Nocardiopsis proteases, preferably of improved thermostability and/or with an amended temperature activity profile. The invention also relates to DNA sequences encoding such variants, their production in a recombinant host cell, as well as methods of using the variants, in particular within the field of animal feed and detergents. The invention furthermore relates to methods of generating and preparing protease variants of amended properties.

Abstract: The present invention relates to novel subtilase variants exhibiting improvements relative to the parent subtilase in one or more properties including: wash performance, thermal stability, storage stability or catalytic activity. The variants of the invention are suitable for use in e.g., cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.

Abstract: (Modified) rice endosperm protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) rice endosperm protein and at least one active ingredient and to their manufacture, as well as to the (modified) rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions, and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a (modified) rice endosperm protein and such a composition, respectively.

Abstract: Provided is a novel method for preparing metabolites of atorvastatin using bacterial cytochrome P450, and a composition therefor, and more particularly, a composition for preparing 2-hydroxylated product of 4-hydroxylated product from atorvastatin including bacterial cytochrome P 450 BM3 (CYP102A1), CYP102A1 mutants, and chimeras derived from the CYP102A1 mutants, a kit therefor, and a method for preparing thereof.

Abstract: This invention provides an Amycolatopsis sp. strain (zhp06), and a method of using the whole cell preparation of the strain for vanillin production. The strain was deposited in China Center for Type Culture Collection on Jul. 26, 2011 with the number of CCTCC NO: M 2011265. Under high concentrations of ferulic acid substrate, the vanillin production by this method can reach more than 10 g/L. The molar conversion rate of ferulic acid is more than 50% and the purity of vanillin is from 80% to 95%. The advantage of this invention includes: repeated use of biocatalyst cells, mild biotransformation condition, low environmental pollution, short production cycle, high product purity and simple purification procedure. It has a great potential for industrial applications.

Abstract: The present invention relates to a method of producing a collagen membrane that has particular mechanical properties.

Abstract: The present invention provides a synthetic regulator of protein function, which regulator is a light-sensitive regulator. The present invention further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present invention further provides methods of modulating protein function, involving use of light. The present invention further provides methods of identifying agents that modulate protein function.

Abstract: Compositions and methods for light controlled protein-protein interactions in a living cell. Two interacting PICL (protein interaction controlled by light) polypeptides are provided. The first polypeptide comprises an LOV (Light, Oxygen or Voltage) domain, which domain is a light sensor that uses flavin mononucleotide (FMN) as a chromophore. The second polypeptide, specifically interacts with the L polypeptide upon light activation of the LOV domain. One or both of the polypeptides are fused to a cellular protein of interest. Upon exposure to light, a targeted interaction between cellular proteins occurs. The ability to regulate protein-protein interactions with subcellular resolution using light is useful for controlling biochemical processes such transcription, receptor activation, protein degradation, synapse formation, etc. in cells and animals.

Abstract: The present invention relates to a novel method of producing 3-hydroxypropionic acid from glycerol, and more particularly to a method of producing 3-hydroxypropionic acid by culturing in a glycerol-containing medium a mutant microorganism obtained by amplifying an aldehyde dehydrogenase-encoding gene in a microorganism having the abilities to produce coenzyme B12 and produce 3-hydroxypropionic acid using glycerol as a carbon source. The present invention enables the fermentation of glycerol even under microaerobic or aerobic conditions without having to add coenzyme B12. Thus, the invention will be very suitable for the development of biological processes for producing large amounts of 3-hydroxypropionic acid.

Abstract: The invention relates to recombinant expression of variant forms of C1 CBH1a and homologs thereof, having improved thermostability, low-pH tolerance, specific activity and other desirable properties. Also provided are methods for producing ethanol and other valuable organic compounds by combining cellobiohydrolase variants with cellulosic materials.

Abstract: Described herein are methods, compositions and synthetic biology approaches for solvent production, including but not limited to butanol production. Described herein are recombinant bacteria and yeast strains which may be used in production of a solvent, including but not limited to butanol, from lignocellulosic and other plant-based feedstocks. Described herein are methods of producing solvents, including but not limited to butanol, using bacteria and yeast strains. Described herein are methods of producing organisms that display highly efficient butanol production.

Abstract: Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.

Abstract: In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites and is covalently linked to a cysteine residue of the lectins; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.

Abstract: Methods and compositions, including nucleotide sequences, amino acid sequences, and host cells, for producing fatty alcohols are described.

Abstract: A transglutaminase protein which is mutated to have improved heat resistance and/or pH stability. A mutation is introduced into WT transglutaminase at a cysteine residue capable of forming a disulfide bond (SS bond).

Abstract: A method of counting protein subunits to determine the oligomeric state of an oligomeric protein complex includes tagging and expressing the protein subunits with a mass/charge tag and selectively removing each mass/charge tag. The number of protein subunits of the oligomeric complex corresponds to the number of mass/charge tags removed.